drugset
Drugs / CD34 selected T-cell depleted allogeneic SCT
last change Dec 2025 re-read 2 minutes ago

CD34 selected T-cell depleted allogeneic SCT

Cell therapy

Developed for
sickle cell disease
Investigated by
Ann & Robert H Lurie Children's Hospital of Chicago · Medical College of Wisconsin · Miltenyi Biomedicine GmbH · New York Medical College · Tufts Medical Center · UCSF Benioff Children's Hospital Oakland
+3 more · University of California, Los Angeles · University of California, San Francisco · Washington University School of Medicine

Trials 1 · a red edge is where a trial was stopped

today NCT01461837 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01461837 Jan 2012 → Dec 2025 overdue sickle cell disease New York Medical College Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD34 selected T-cell depleted allogeneic SCT ClinicalTrials.gov intervention name — accepted as the source's own label NCT01461837 ↗
Modality Cell therapy “infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation” NCT01461837 ↗